Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY5R | Q15761 | 4/20 | 0.45 |
| ▸ | ACACB | O00763 | 2/20 | 0.44 |
| ▸ | ACACA | Q13085 | 1/20 | 0.44 |
| ▸ | MCHR1 | Q99705 | 8/20 | 0.44 |
| ▸ | ADRA2A | P08913 | 4/20 | 0.44 |
| ▸ | P2RX7 | Q99572 | 4/20 | 0.42 |
| ▸ | NAPEPLD | Q6IQ20 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6464256 | 1.00 | NPY5R (0.45) | NPY5RACACBACACAMCHR1ADRA2A | |
| SCHEMBL6876778 | 0.94 | MCHR1 (0.43) | NPY5RACACBACACAMCHR1ADRA2A | |
| SCHEMBL6876783 | 0.94 | MCHR1 (0.43) | NPY5RACACBACACAMCHR1ADRA2A | |
| SCHEMBL6463492 | 0.94 | NPY5R (0.47) | NPY5RACACBACACAMCHR1ADRA2A | |
| SCHEMBL6463499 | 0.94 | NPY5R (0.47) | NPY5RACACBACACAMCHR1ADRA2A | |
| SCHEMBL6873098 | 0.90 | ACACB (0.47) | NPY5RACACBACACAMCHR1ADRA2A | |
| SCHEMBL6873100 | 0.90 | ACACB (0.47) | NPY5RACACBACACAMCHR1ADRA2A | |
| SCHEMBL6875578 | 0.90 | MCHR1 (0.47) | NPY5RACACBACACAMCHR1ADRA2A | |
| SCHEMBL6875585 | 0.90 | MCHR1 (0.47) | NPY5RACACBACACAMCHR1ADRA2A | |
| SCHEMBL6876773 | 0.89 | MCHR1 (0.46) | NPY5RACACBACACAMCHR1ADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050197350-A1 | Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof | TAISHO PHARMACEUTICAL CO., LTD. | 2005-09-08 | — | — | US | claimed |
| WO-2004087669-A1 | NOVEL QUINOLINE, TETRAHYDROQUINAZOLINE, AND PYRIMIDINE DERIVATIVES AND METHODS OF TREATMENT RELATED TO THE USE THEREOF | TAISHO PHARMACEUTICAL CO. LTD. (JP) | 2004-10-14 | — | — | WO | claimed |
| EP-1464335-A2 | Quinoline, tetrahydroquinoline and pyrimidine derivatives as mch antagonist | Taisho Pharmaceutical Co. Ltd. (JP) | 2004-10-06 | — | — | EP | claimed |
| US-20050197350-A1 | Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof | TAISHO PHARMACEUTICAL CO., LTD. | 2005-09-08 | — | — | US | disclosed |
| WO-2004087669-A1 | NOVEL QUINOLINE, TETRAHYDROQUINAZOLINE, AND PYRIMIDINE DERIVATIVES AND METHODS OF TREATMENT RELATED TO THE USE THEREOF | TAISHO PHARMACEUTICAL CO. LTD. (JP) | 2004-10-14 | — | — | WO | disclosed |
| EP-1464335-A2 | Quinoline, tetrahydroquinoline and pyrimidine derivatives as mch antagonist | Taisho Pharmaceutical Co. Ltd. (JP) | 2004-10-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050197350-A1 | Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof | HCRTR2, MCHR1, MCHR2 | NPY5R 8/4885ACACB 3035/4885ACACA 2602/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.